» Articles » PMID: 10347755

MHC-restricted Antigen Presentation and Recognition: Constraints on Gene, Recombinant and Peptide Vaccines in Humans

Overview
Date 1999 May 29
PMID 10347755
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The target of any immunization is to activate and expand lymphocyte clones with the desired recognition specificity and the necessary effector functions. In gene, recombinant and peptide vaccines, the immunogen is a single protein or a small assembly of epitopes from antigenic proteins. Since most immune responses against protein and peptide antigens are T-cell dependent, the molecular target of such vaccines is to generate at least 50-100 complexes between MHC molecule and the antigenic peptide per antigen-presenting cell, sensitizing a T cell population of appropriate clonal size and effector characteristics. Thus, the immunobiology of antigen recognition by T cells must be taken into account when designing new generation peptide- or gene-based vaccines. Since T cell recognition is MHC-restricted, and given the wide polymorphism of the different MHC molecules, distinct epitopes may be recognized by different individuals in the population. Therefore, the issue of whether immunization will be effective in inducing a protective immune response, covering the entire target population, becomes an important question. Many pathogens have evolved molecular mechanisms to escape recognition by the immune system by variation of antigenic protein sequences. In this short review, we will discuss the several concepts related to selection of amino acid sequences to be included in DNA and peptide vaccines.

Citing Articles

Epitope Selection for Fighting Visceral Leishmaniosis: Not All Peptides Function the Same Way.

Martinez-Rodrigo A, Mas A, Alvarez-Campos D, Orden J, Dominguez-Bernal G, Carrion J Vaccines (Basel). 2020; 8(3).

PMID: 32630347 PMC: 7564088. DOI: 10.3390/vaccines8030352.


Identification of BALB/c Immune Markers Correlated with a Partial Protection to Leishmania infantum after Vaccination with a Rationally Designed Multi-epitope Cysteine Protease A Peptide-Based Nanovaccine.

Agallou M, Margaroni M, Athanasiou E, Toubanaki D, Kontonikola K, Karidi K PLoS Negl Trop Dis. 2017; 11(1):e0005311.

PMID: 28114333 PMC: 5295723. DOI: 10.1371/journal.pntd.0005311.


Identification of novel epitopes from human papillomavirus type 18 E7 that can sensitize PBMCs of multiple HLA class I against human cervical cancer.

Kim S, Chung H, Lee K, Lim J J Transl Med. 2014; 12:229.

PMID: 25141788 PMC: 4145224. DOI: 10.1186/s12967-014-0229-7.


Experimental Validation of Multi-Epitope Peptides Including Promising MHC Class I- and II-Restricted Epitopes of Four Known Leishmania infantum Proteins.

Agallou M, Athanasiou E, Koutsoni O, Dotsika E, Karagouni E Front Immunol. 2014; 5:268.

PMID: 24959167 PMC: 4051127. DOI: 10.3389/fimmu.2014.00268.


Helper T cell epitope-mapping reveals MHC-peptide binding affinities that correlate with T helper cell responses to pneumococcal surface protein A.

Singh R, Singh S, Sharma P, Singh U, Briles D, Hollingshead S PLoS One. 2010; 5(2):e9432.

PMID: 20195541 PMC: 2828482. DOI: 10.1371/journal.pone.0009432.